Exact Sciences Corp. stock (US30063P1057): Q4 2025 earnings miss on EPS despite revenue beat

Exact Sciences Corp. reported Q4 2025 results with EPS of -$0.21, missing consensus, while revenue rose 23.1% year?over?year to $878.38 million.

Exact Sciences Corp. stock has come under pressure after the company’s fourth?quarter 2025 earnings release showed a wider?than?expected loss per share, even as revenue grew strongly and topped analysts’ estimates. On February 13, 2026, Exact Sciences announced Q4 2025 results with earnings per share of -$0.21, missing the consensus estimate of $0.08 by $0.29, according to MarketBeat’s earnings summary as of May 07, 2026. Quarterly revenue climbed 23.1% year?over?year to $878.38 million, above the consensus forecast of $860.59 million, signaling continued top?line momentum despite ongoing profitability challenges.

For the full year, Exact Sciences reported annual revenue of about $3.25 billion and a net loss of roughly $207.95 million, reflecting a trailing EPS of -$1.10 over the last four quarters, per MarketBeat data as of May 07, 2026. Analysts expect earnings to turn positive next year, with projected EPS improving from an estimated -$0.58 to about $0.50 per share, indicating that the market is pricing in a path toward profitability even as the company continues to invest in its cancer?screening portfolio and commercial infrastructure.

As of May 07, 2026, Exact Sciences had a market capitalization of approximately $20.03 billion, according to StockInvest.us, underscoring its position as a mid?cap player in the US diagnostics and life?sciences sector. The stock trades on the Nasdaq under the ticker EXAS, giving US retail investors direct access to the company’s performance in the cancer?screening and molecular diagnostics space.

By the editorial team – specialized in equity coverage.

At a glance

• Name: Exact Sciences Corp.
• Sector/industry: Healthcare, diagnostics and life sciences
• Headquarters/country: United States
• Core markets: United States, with some international exposure
• Key revenue drivers: Cancer?screening tests (including Cologuard and other molecular diagnostics), lab services, and related products
• Home exchange/listing venue: Nasdaq (ticker: EXAS)
• Trading currency: US dollar (USD)

Exact Sciences Corp.: core business model

Exact Sciences Corp. focuses on developing and commercializing cancer?screening and molecular diagnostic tests, primarily aimed at early detection and risk assessment. The company’s flagship product, Cologuard, is a non?invasive stool?based test for colorectal cancer screening that has become a key driver of its US revenue base. In addition to Cologuard, Exact Sciences offers a portfolio of laboratory?developed tests and companion diagnostics used in oncology and other therapeutic areas, serving physicians, health?system partners, and payers.

The company’s business model combines proprietary test development, centralized laboratory operations, and a direct?to?consumer and provider?focused commercial strategy. Exact Sciences invests heavily in clinical research and regulatory submissions to expand test indications and secure reimbursement from Medicare, Medicaid, and private insurers. This approach allows the firm to scale its test volumes and lab throughput, but it also entails significant upfront R&D and commercialization costs, which contribute to the current pattern of strong revenue growth alongside net losses.

Main revenue and product drivers for Exact Sciences Corp.

Exact Sciences’ main revenue driver remains its colorectal cancer?screening franchise, anchored by Cologuard, which targets average?risk adults who may be reluctant to undergo traditional colonoscopy. The company has also expanded into other cancer?screening areas, including multi?cancer early detection and liquid?biopsy?based tests, aiming to capture a broader share of the preventive?care and oncology diagnostics markets. These newer offerings are still in earlier stages of adoption but represent a key growth vector for the company.

Lab services and related products, including sample collection kits and laboratory processing, also contribute meaningfully to revenue. Over the past several years, Exact Sciences has grown its annual revenue at a compound annual growth rate of about 61%, according to Alpha Spread data as of May 07, 2026, reflecting strong demand for its screening tests and expanding test volumes. Analysts project a more moderate but still robust CAGR of roughly 12% over the next three years, suggesting that the company is transitioning from hyper?growth to a more sustainable expansion phase.

Why Exact Sciences Corp. matters for US investors

Exact Sciences Corp. is relevant for US investors because it operates at the intersection of healthcare innovation, preventive medicine, and the growing demand for early?detection cancer tests. As the US population ages and healthcare systems seek cost?effective ways to reduce late?stage cancer diagnoses, companies that can deliver accurate, non?invasive screening tools stand to benefit from structural tailwinds. Exact Sciences’ listing on the Nasdaq provides US retail investors with a liquid, dollar?denominated exposure to this theme.

For investors focused on growth?oriented healthcare names, Exact Sciences offers a leveraged play on the adoption of molecular diagnostics and multi?cancer screening. However, the company’s current unprofitable profile and reliance on continued investment in R&D and commercialization mean that its stock can be volatile, particularly around earnings releases and regulatory or reimbursement developments. This makes Exact Sciences more suitable for investors with a higher risk tolerance and a longer time horizon who can tolerate interim losses in exchange for potential long?term growth.

Conclusion

Exact Sciences Corp. continues to post strong revenue growth, with Q4 2025 sales rising 23.1% year?over?year to $878.38 million, even as the company reports net losses and EPS that lag analyst expectations. The stock trades on the Nasdaq with a market capitalization of about $20.03 billion, giving US investors direct exposure to a high?growth cancer?screening and molecular diagnostics business. While analysts project a path toward positive earnings in the coming year, Exact Sciences remains a speculative growth name with meaningful execution and reimbursement risks.

Investors considering Exact Sciences Corp. should weigh the company’s innovative product pipeline and expanding test volumes against its current unprofitable profile and the competitive dynamics in the diagnostics and oncology?screening space. The stock may appeal to those seeking long?term growth in healthcare innovation, but it is less suited for conservative or income?oriented portfolios. As with any equity investment, diversification and a clear understanding of risk tolerance are important when evaluating a position in Exact Sciences Corp.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.